DiaMedica Q2 2026 net loss widens to $10.1 million; cash falls to $43.5 million
DiaMedica reported a second-quarter 2026 net loss of $10.1 million, up from $7.7 million a year earlier, as R&D spending rose. The company had $43.5 million in cash and investments at June 30, 2026, down from $59.9 million at December 31, 2025, and said this should fund planned studies and operations through 2027. The filing also reports positive preeclampsia Phase 2 topline results, which shareholders will weigh against the higher losses and lower cash balance.
Key points
- Q2 2026 net loss was $10.1 million, or $0.19 per share, versus a net loss of $7.7 million, or $0.18 per share, in Q2 2025.
- Six-month net loss was $20.2 million, up from $15.4 million; R&D expenses for the six months were $16.1 million, up from $11.5 million.
- Cash, cash equivalents and short-term investments were $43.5 million at June 30, 2026, versus $59.9 million at December 31, 2025; the company expects to fund operations through 2027.
- Preeclampsia Phase 2 Part 1a reported a mean 29.1 mmHg reduction in systolic blood pressure in the combined final cohorts; the company will hold a key opinion leader call with FGR topline results in September.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.